FDA approves Trelegy Ellipta as once-daily single inhaler triple therapy for asthma and COPD

This article was originally published here

The FDA-approved strength for both COPD and asthma is fluticasone furoate / umeclidinium / vilanterol 100/62.5/25mcg. There is an additional strength for asthma alone which is fluticasone furoate

The post FDA approves Trelegy Ellipta as once-daily single inhaler triple therapy for asthma and COPD appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply